Efficacy and safety of pembrolizumab on cervical cancer: A systematic review and single-arm meta-analysis

Qi, Lin; Li, Ning; Lin, Aimin; Wang, Xiuli; Cong, Jianglin

doi:10.3389/fonc.2022.910486

Cited by 8 publications

(7 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, bevacizumab has been investigated in combination with chemotherapy in advanced cervical cancer and has shown improvement in overall survival [ 69 ]. Pembrolizumab has shown activity in advanced or recurrent cervical cancer and has been approved for certain patients with advanced disease [ 70 ]. Niraparib and rucaparib have shown promise in clinical trials for the treatment of recurrent or metastatic cervical cancer, particularly in patients with certain genetic mutations, such as BRCA1/2 [ 71 ].…”

Section: Future Improvement Strategies In Cervical Cancer Treatmentmentioning

confidence: 99%

Current Therapeutic Approaches in Cervical Cancer Based on the Stage of the Disease: Is There Room for Improvement?

Dicu-Andreescu,

Marincaș,

Ungureanu

et al. 2023

Medicina

View full text Add to dashboard Cite

Cervical cancer continues to be among the most common malignancies in women, and in recent decades, important measures have been taken to reduce its incidence. The first and most important steps to achieve this goal are oriented toward prevention through screening programs and vaccination, mainly against oncogenic human papillomavirus (HPV) strains 16 and 18. The therapeutic approach is based on the diagnosis and treatment guidelines for cervical cancer, which establish for each stage (FIGO, TNM) specific conduct. These guidelines summarize quite precisely the elements of therapeutic practice, but, in some places, they leave optional variants based on which nuanced approaches could be established. Adherence to these guidelines, which include the performing of minor or major surgery, with or without chemotherapy and radiation therapy, combined with advanced imaging investigations, has been able to lead to a substantial increase in survival. The purpose of this literature review is to discuss the diagnosis and treatment options in cervical cancer depending on the histological type, FIGO staging, and patient performance index, taking into account the hospital resources available in middle-income countries (percentage of gross domestic product allocated to health services around 5.5%, in the case of Romania).

show abstract

Section: Future Improvement Strategies In Cervical Cancer Treatmentmentioning

confidence: 99%

Current Therapeutic Approaches in Cervical Cancer Based on the Stage of the Disease: Is There Room for Improvement?

Dicu-Andreescu,

Marincaș,

Ungureanu

et al. 2023

Medicina

View full text Add to dashboard Cite

show abstract

“…This is now considered the standard of care for patients with PD-L1 scores of at least 1 and persistent, metastatic, or recurrent disease. 63,64…”

Section: Advances In Persistent Metastatic and Recurrent Diseasementioning

confidence: 99%

“…This is now considered the standard of care for patients with PD-L1 scores of at least 1 and persistent, metastatic, or recurrent disease. 63,64 In 2022, Tewari and colleagues 61 reported results for another anti-PD-L1 agent, cemiplimab. In a phase 3 trial, they evaluated the use of cemiplimab alone compared with investigator's choice of single-agent chemotherapy in patients with recurrent cervical cancer who previously received first-line platinum chemotherapy.…”

Section: Advances In Persistent Metastatic and Recurrent Diseasementioning

confidence: 99%

Improving Therapies for Cervical Cancer While Working Toward Eradication

Boitano,

Kako,

Leath

2023

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Despite effective screening strategies and the development and implementation of prophylactic high-risk human papillomavirus vaccination, cervical cancer remains a significant public health burden. This burden is most pronounced in under-resourced countries without fully developed screening and vaccination programs, although the disease remains present worldwide, including in industrialized countries. To that end, the World Health Organization (WHO) has an active focus on the elimination of cervical cancer, with objective metrics to be achieved by countries by the year 2030. Although increased vaccination and screening will be needed to approach potential eradication of cervical cancer, as recognized by the WHO initiative, treatment will need to continue to not only be effective in the near term, but to improve outcomes as well. Accordingly, assessments to improve primary treatment options, including surgery for women with early-stage disease, modification of chemoradiation for those with locally advanced cervical cancer, and systemic therapy for those with recurrent or metastatic presentations, are ongoing. Accordingly, we highlight important areas of both recent and ongoing focus as they relate to improving cervical cancer outcomes.

show abstract

“…PD-1 and PD-L1 inhibitors have shown efficacy in several solid tumors, leading to improved survival outcomes [ 15 ]. For example, pembrolizumab has been approved for PD-L1-positive cervical cancer based on improved overall survival and progression-free survival rates compared to chemotherapy in clinical trials like KEYNOTE-158 [ 16 ]. Atezolizumab specifically has been evaluated in several phase I and II trials for PD-L1-positive cancers [ 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Atezolizumab as a PD-L1 Inhibitor in the Treatment of Cervical Cancer: A Systematic Review

Velimirovici,

Feier,

Vonica

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Background and objectives: The efficacy and safety of PD-L1 inhibitors in the treatment of cervical cancer is an ongoing research question. This review aims to establish a clear profile of atezolizumab, examining its impact on survival outcomes, response rates, and safety measured by serious adverse events (SAEs). Materials and methods: A literature search was conducted using PubMed, Scopus, and Web of Science, focusing on articles published up to February 2024. The review followed the PRISMA guidelines and synthesized outcomes from four randomized trial studies involving atezolizumab administered at 1200 mg IV every three weeks, alone or in combination with chemoradiotherapy. Results: A total of 284 patients received atezolizumab, the majority being advanced stage cervical cancer (IVA-IVB). Median follow-up times ranged from 9 weeks to 32.9 months. It was found that combining atezolizumab with standard therapies extended median progression-free survival (PFS) from 10.4 to 13.7 months and overall survival (OS) from 22.8 to 32.1 months, according to the phase III trial. Monotherapy and initial treatment settings with atezolizumab also showed promising efficacy, with disease-free survival rates at 24 months reaching 79% compared to 52% with standard therapy alone. However, the treatment was associated with high rates of SAEs, reaching up to 79% in more intensive treatment combinations. Conclusions: Atezolizumab demonstrates significant potential in improving PFS and OS in patients with cervical cancer, supporting its inclusion as a first-line treatment option. Despite the efficacy benefits, the high incidence of SAEs necessitates careful patient selection and management strategies to mitigate risks. This systematic review supports the continued evaluation of atezolizumab in broader clinical trials to refine its therapeutic profile and safety measures in the context of cervical cancer treatment.

show abstract

Efficacy and safety of pembrolizumab on cervical cancer: A systematic review and single-arm meta-analysis

Cited by 8 publications

References 59 publications

Current Therapeutic Approaches in Cervical Cancer Based on the Stage of the Disease: Is There Room for Improvement?

Current Therapeutic Approaches in Cervical Cancer Based on the Stage of the Disease: Is There Room for Improvement?

Improving Therapies for Cervical Cancer While Working Toward Eradication

Efficacy and Safety of Atezolizumab as a PD-L1 Inhibitor in the Treatment of Cervical Cancer: A Systematic Review

Contact Info

Product

Resources

About